# Study Guide: VA/DOD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea This study guide is designed to synthesize the clinical evidence and management pathways outlined in the 2025 VA/DOD Clinical Practice Guideline. It provides a comprehensive overview of diagnostic criteria, screening tools, and evidence-based treatment strategies for chronic insomnia disorder and obstructive sleep apnea (OSA). --- ## I. Key Concepts and Clinical Framework ### 1. Diagnostic Definitions and Scope * **Chronic Insomnia Disorder:** Characterized by persistent difficulty with sleep initiation or maintenance (occurring at least three times per week for more than three months) despite adequate opportunity for sleep. It must be accompanied by daytime impairment (e.g., fatigue, mood disturbance, or impaired concentration). Diagnosis is primarily clinical; objective measures like polysomnography (PSG) are not required unless other disorders are suspected. * **Obstructive Sleep Apnea (OSA):** A sleep-disordered breathing condition involving upper airway collapse, leading to partial (hypopnea) or complete (apnea) airflow interruption. * **Apnea:** $\ge$ 90% decrease in airflow for at least 10 seconds. * **Hypopnea:** $\ge$ 30% decrease in airflow for at least 10 seconds associated with $\ge$ 3% oxygen desaturation or arousal. * **COMISA:** The presence of comorbid insomnia and obstructive sleep apnea. This condition is highly prevalent in military and Veteran populations and often results in higher morbidity than either condition alone. ### 2. Screening and Diagnostic Tools The guideline emphasizes the use of validated instruments to identify patients requiring further evaluation: * **Insomnia Screening:** Insomnia Severity Index (ISI) and Athens Insomnia Scale (AIS). * **OSA Screening:** STOP questionnaire (Snoring, Tiredness, Observed apnea, high blood Pressure). A score of $\ge$ 2 indicates high risk. * **Objective Testing for OSA:** * **Polysomnography (PSG):** The "gold standard" in-lab test. * **Home Sleep Apnea Testing (HSAT):** Appropriate for uncomplicated patients with high pretest probability of moderate-to-severe OSA. A negative HSAT cannot rule out OSA and should prompt repeat testing or PSG. ### 3. OSA Severity Categorization Severity is traditionally determined by the Apnea-Hypopnea Index (AHI) or Respiratory Event Index (REI): | Severity | Events per Hour | | :--- | :--- | | **Mild** | $\ge$ 5 to < 15 (with symptoms) | | **Moderate** | $\ge$ 15 to < 30 | | **Severe** | $\ge$ 30 | ### 4. Management Paradigms * **Patient-Centered Care (PCC):** Individualizing treatment based on patient needs, characteristics, and values. * **Shared Decision Making (SDM):** A collaborative process where providers and patients weigh the risks and benefits of various care options. * **Stepped Care:** Ensuring specialized expertise is targeted effectively, starting with the least intensive effective intervention. --- ## II. Treatment Recommendations ### Chronic Insomnia Disorder * **First-Line Treatment:** Cognitive Behavioral Therapy for Insomnia (CBT-I) is strongly recommended over pharmacotherapy. * **Behavioral Interventions:** * **CBT-I:** Multi-component (sleep restriction, stimulus control, cognitive restructuring). * **BBT-I (Brief Behavioral Treatment):** Focuses on behavioral components like sleep restriction and stimulus control. * **Pharmacotherapy (Suggested Agents):** If behavioral therapy is insufficient or unavailable, suggested agents include Dual Orexin Receptor Antagonists (DORAs like Daridorexant, Lemborexant, Suvorexant), Doxepin (low-dose), and non-benzodiazepine receptor agonists (Zolpidem, Eszopiclone, Zaleplon). * **Avoidance:** The guideline suggests against the use of antipsychotics, benzodiazepines, diphenhydramine, trazodone, and most herbal supplements (kava, melatonin, valerian) as stand-alone treatments for chronic insomnia. ### Obstructive Sleep Apnea * **Primary Therapies:** Positive Airway Pressure (PAP) and Mandibular Advancement Devices (MAD) are recommended. * **PAP Specifics:** Auto-titrating PAP (APAP) is suggested over fixed CPAP for new diagnoses to facilitate usage. * **MAD Therapy:** Suggested as a first-line option for mild-to-moderate OSA, particularly for patients who prefer it or have lifestyle limitations (e.g., military personnel in austere environments). * **Surgical Options:** Referral for hypoglossal nerve stimulation (HGNS) is suggested for appropriate patients with AHI $\ge$ 15 who have failed PAP. * **Adjunctive Treatments:** Evidence-based weight management is suggested for patients with overweight or obesity. Positional therapy is suggested for positional OSA. --- ## III. Short-Answer Practice Questions 1. **What are the three specific requirements for a diagnosis of "chronic" insomnia disorder?** * *Answer:* Sleep difficulty occurring at least 3 times per week, lasting for more than 3 months, and resulting in daytime impairment/consequence. 2. **Why is a negative Home Sleep Apnea Test (HSAT) considered insufficient to rule out OSA?** * *Answer:* HSAT is designed to "rule in" OSA. Because it can produce false negatives, a non-diagnostic result in a high-pretest-probability patient requires follow-up with a repeat HSAT or in-lab PSG. 3. **Contrast CBT-I and BBT-I.** * *Answer:* CBT-I is a multi-session treatment including behavioral (sleep restriction, stimulus control) and cognitive components (restructuring). BBT-I is a shorter intervention focused primarily on the behavioral components. 4. **Which pharmacologic agents for insomnia are categorized as Dual Orexin Receptor Antagonists (DORAs)?** * *Answer:* Daridorexant, Lemborexant, and Suvorexant. 5. **Under what circumstances is Mandibular Advancement Device (MAD) therapy preferred over PAP?** * *Answer:* For mild-to-moderate OSA, patient preference, or when the patient lives/works in environments where PAP is unfeasible (e.g., lack of electricity or distilled water). 6. **What is the "STOP" acronym used for in OSA screening?** * *Answer:* Snoring, Tiredness, Observed apnea, and high blood Pressure. 7. **Identify three contraindications or conditions requiring the delay of CBT-I/BBT-I.** * *Answer:* (Any three) Medically unstable, active substance use disorder, uncontrolled seizure disorder, current acute mental health symptoms, or engagement in exposure-based PTSD treatment. 8. **What is the recommendation regarding sleep hygiene education as a monotherapy?** * *Answer:* It is suggested against as a stand-alone treatment because it is significantly less effective than CBT-I or BBT-I. --- ## IV. Essay Prompts for Deeper Exploration 1. **The Military Phenotype:** Discuss why insomnia and OSA are highly prevalent in the Department of Defense and Veteran populations. Analyze the specific operational and health impacts (e.g., suicide risk, deployment readiness) that make the management of sleep disorders a priority for these departments. 2. **The Challenge of COMISA:** Explain the clinical complexity of treating a patient diagnosed with both chronic insomnia and OSA. How does the presence of one disorder complicate the treatment adherence of the other, and what integrated management strategies does the guideline suggest? 3. **Pharmacotherapy vs. Behavioral Intervention:** Evaluate the risks and benefits of using sedative-hypnotic medications for chronic insomnia. Incorporate the FDA safety announcements regarding non-benzodiazepine receptor agonists and the Beers Criteria for elderly patients in your analysis. 4. **Surgical Interventions in OSA:** Critically analyze the criteria for referring a patient for Hypoglossal Nerve Stimulation (HGNS). What are the specific FDA requirements, and what role does "mean disease alleviation" play in evaluating surgical success versus traditional PAP therapy? --- ## V. Glossary of Important Terms * **AHI (Apnea-Hypopnea Index):** The average number of apneas and hypopneas per hour of sleep. * **AIS (Athens Insomnia Scale):** A validated 8-item screening tool for insomnia. * **APAP (Auto-titrating Positive Airway Pressure):** A device that automatically adjusts the pressure level on a breath-by-breath basis to maintain airway patency. * **Beers Criteria:** A list of potentially inappropriate medications for older adults, often used to caution against certain insomnia drugs. * **CBT-I (Cognitive Behavioral Therapy for Insomnia):** The gold-standard, multi-component behavioral treatment for chronic insomnia. * **DORA (Dual Orexin Receptor Antagonist):** A class of insomnia medication that promotes sleep by blocking wake-promoting neuropeptides. * **HGNS (Hypoglossal Nerve Stimulation):** An implanted neurostimulator that stimulates the tongue muscles to prevent airway collapse. * **HSAT (Home Sleep Apnea Testing):** An unattended sleep study performed in the patient's home, typically measuring fewer channels than a PSG. * **ISI (Insomnia Severity Index):** A 7-item screening instrument used to assess the severity of insomnia symptoms. * **MAD (Mandibular Advancement Device):** A dental appliance that holds the lower jaw forward to keep the airway open during sleep. * **PSG (Polysomnography):** An attended, overnight in-laboratory sleep study measuring multiple physiological parameters. * **REI (Respiratory Event Index):** A measure of OSA severity used specifically in HSAT, calculating events per hour of recording time rather than sleep time. * **SOL (Sleep Onset Latency):** The amount of time it takes to transition from full wakefulness to sleep. * **WASO (Wake After Sleep Onset):** The total time spent awake after initially falling asleep and before final awakening.